Skip to main content
Welcome to
super saver spring
offer ends april 20
save over $140
save over 85%
$0.99
per week for 24 weeks
Welcome to
super saver spring
$0.99
per week
for 24 weeks
// //

This has been a strong year for biotech, beyond heightened interest in companies developing COVID-19 treatments, with stocks of several drug developers spiking after their Nasdaq IPOs.

Reuters

Montreal cancer drug developer Repare Therapeutics Inc. increased the target size of its Nasdaq initial public offering by more than half on Monday, saying it could raise up to US$152-million.

Repare said in a filing with the U.S. Securities and Exchange Commission it will offer 7.4 million shares at US$16 to US$18 each. Its underwriters have the option to buy another 1.1 million shares. If successful, the IPO would value Repare at US$500-million-plus. Repare had revealed plans to raise US$100-million on May 29.

Repare was the first of three Canadian biotech startups to unveil plans to go public in the United States in recent weeks. In early June, Hamilton cancer treatment developer Fusion Pharmaceuticals Inc. filed a registration statement to go public on Nasdaq and Chinook Therapeutics Inc., a kidney-disease drug developer jointly based in Vancouver and Seattle, said it would merge with Nasdaq-traded Aduro Biotech Inc.

Story continues below advertisement

Canada’s biotech sector has flourished recently, despite limited Canadian institutional investor interest outside Quebec. Companies raised a record $921-million in venture capital last year, while Clementia Pharmaceuticals Inc. and BlueRock Therapeutics, sold to foreign drug companies in US$1-billion deals. Three other Canadian biotechs either went public or cross-listed on Nasdaq in 2019. Lupus drug developer Aurinia Pharmaceuticals Inc. recently filed the first new drug application in years by a Canadian firm with the U.S. Food and Drug Administration, after positive trials in 2019.

This has been a strong year for biotech, beyond heightened interest in companies developing COVID-19 treatments, with stocks of several drug developers spiking after their Nasdaq IPOs.

Repare is aiming to create “precision oncology" drugs that attack genetic defects in cancerous tumors, preventing toxic cells from repairing their DNA. Repare aims to get its lead drug candidate into human trials this summer. In May it struck a partnership with Bristol Myers Squibb to identify drug candidates.

Your time is valuable. Have the Top Business Headlines newsletter conveniently delivered to your inbox in the morning or evening. Sign up today.

Your Globe

Build your personal news feed

  1. Follow topics and authors relevant to your reading interests.
  2. Check your Following feed daily, and never miss an article. Access your Following feed from your account menu at the top right corner of every page.

Follow the author of this article:

Follow topics related to this article:

View more suggestions in Following Read more about following topics and authors
Report an error Editorial code of conduct
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

If you do not see your comment posted immediately, it is being reviewed by the moderation team and may appear shortly, generally within an hour.

We aim to have all comments reviewed in a timely manner.

Comments that violate our community guidelines will not be posted.

UPDATED: Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies